Truist Securities Maintains Buy on Guardian Pharmacy Service, Raises Price Target to $51
Truist Securities analyst David Macdonald maintains Guardian Pharmacy Service (NYSE:GRDN) with a Buy and raises the price target from $47 to $51.
Share
Why It Matters
A big investing firm thinks Guardian Pharmacy is worth more money now. This shows the company might be doing well and growing its business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.